Thomas Sciascia R.'s Insider Trades & SAST Disclosures
Thomas Sciascia R.'s most recent trade in Trevi Therapeutics Inc was a trade of 2,631 Common Stock done at an average price of $6.6 . Disclosure was reported to the exchange on March 25, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Thomas Sciascia R..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 6.60 per share. | 25 Mar 2025 | 2,631 | 221,373 (1%) | 0% | 6.6 | 17,365 | Common Stock |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 25 Mar 2025 | 2,631 | 224,004 (1%) | 0% | 1.4 | 3,762 | Common Stock |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2025 | 2,631 | 0 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 32,000 | 32,000 | - | - | Performance Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 116,000 | 116,000 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 19 Aug 2024 | 16,496 | 236,811 (1%) | 0% | 1.4 | 23,589 | Common Stock |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 16,496 | 0 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.96 per share. | 19 Aug 2024 | 16,496 | 220,315 (1%) | 0% | 3.0 | 48,883 | Common Stock |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2024 | 18,660 | 16,496 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.76 per share. | 14 Aug 2024 | 18,660 | 220,315 (1%) | 0% | 2.8 | 51,440 | Common Stock |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 14 Aug 2024 | 18,660 | 238,975 (1%) | 0% | 1.4 | 26,684 | Common Stock |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.79 per share. | 14 Aug 2024 | 12,745 | 220,315 (1%) | 0% | 2.8 | 35,513 | Common Stock |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 14 Aug 2024 | 12,745 | 233,060 (1%) | 0% | 1.4 | 18,225 | Common Stock |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2024 | 12,745 | 35,156 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.75 per share. | 14 Aug 2024 | 100 | 220,315 (1%) | 0% | 2.8 | 275 | Common Stock |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 14 Aug 2024 | 100 | 220,415 (1%) | 0% | 1.4 | 143 | Common Stock |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2024 | 100 | 47,901 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2024 | 59,354 | 0 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 29 May 2024 | 59,354 | 267,801 (1%) | 0% | 2.2 | 129,985 | Common Stock |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.55 per share. | 29 May 2024 | 53,368 | 214,433 (1%) | 0% | 2.6 | 136,110 | Common Stock |
| Trevi Therapeutics Inc | Thomas Sciascia R. | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 187,500 | 187,500 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2022 | 7,500 | 37,500 | - | - | Performance Stock Options (right to buy) | |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2022 | 30,000 | 30,000 | - | - | Performance Stock Options (right to buy) | |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Thomas R. Sciascia | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 50,000 | 50,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges